On August 22, 2023, the U.S. Court of Appeals for the Federal Circuit issued yet another decision reinforcing what can only be described as the “lead compound” rule for challenging pharmaceutical and other chemical compound patents on the basis of obviousness.
Material that is recited in the specification of a patent application is certainly part of the disclosure. In the United States (and in many other jurisdictions), additional material that is not explicitly written.